ID | 53024 |
JaLCDOI | |
フルテキストURL | |
著者 |
Yamamoto, Tsuyoshi
Iwakuni Clinical Center, National Hospital Organization
Kajikawa, Yutaka
Fukuyama Medical Center,National Hospital Organization
Otani, Satoru
Iwakuni Clinical Center, National Hospital Organization
Yamada, Yuki
Iwakuni Clinical Center, National Hospital Organization
Takemoto, Syunji
Fukuyama Medical Center,National Hospital Organization
Hirota, Minoru
Fukuyama Medical Center,National Hospital Organization
Ikeda, Masae
Fukuyama Medical Center,National Hospital Organization
Iwagaki, Hiromi
Fukuyama Medical Center,National Hospital Organization
Fujiwara, Toshiyoshi
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
|
抄録 | Accumulated studies have shown that ω-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) have protective roles against inflammatory responses such as hyperlipidemia, diabetes mellitus (DM) and cardiovascular diseases. Here we examined the effects of administering EPA to hyperlipidemic patients and other patients undergoing cardiac surgery to determine whether this treatment would increase plasma EPA levels and to clarify the association between EPA treatment and adiponectin production in hyperlipidemic patients. We also assessed the effect of preoperative EPA administration on postoperative adverse events such as postoperative atrial fibrillation (POAF) and postoperative infection in the cardiac surgery patients. The EPA administration significantly increased the serum EPA concentrations in both patient populations (p<0.001). In the hyperlipidemic patients, the EPA administration significantly increased plasma adiponectin levels (p<0.05), accompanied by a decrease in insulin resistance designated by the HOMA-IR (homeostasis model assessment of insulin resistance) score (p<0.05) and Hs-CRP (high sensitivity C-reactive protein) value (p<0.05). In the cardiac surgery patients, no significant effect of EPA on cardiac adverse events such as POAF was observed. However, our results clearly demonstrated that both the neutrophil-to-lymphocyte ratio and the 2nd-line antibiotic requirement in the EPA group were significantly decreased compared to the untreated control group (p<0.05). We suggest that EPA administration may exert anti-inflammatory effects in patients with hyperlipidemia and in those undergoing cardiac surgery, possibly through an increase in plasma adiponectin levels.
|
キーワード | eicosapentaenoic acid
adiponectin
hyperlipidemic patients
cardiac surgery
atrial fibrillation
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2014-12
|
巻 | 68巻
|
号 | 6号
|
出版者 | Okayama University Medical School
|
開始ページ | 349
|
終了ページ | 361
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2014 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT | |
関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/53125
|